Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The evolution to stool DNA testing for colorectal cancer.

K S Tagore1, T R Levin, M J Lawson

  • 1University of California Davis Medical Center, Sacramento, CA, USA.

Alimentary Pharmacology & Therapeutics
|June 12, 2004
PubMed
Summary

Colorectal cancer screening faces challenges with current methods. Advanced stool-based DNA testing offers a promising noninvasive strategy for early detection and improved patient adherence.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exploration of fs-laser ablation parameter space for 2D/3D imaging of soft and hard materials by tri-beam microscopy.

Ultramicroscopy·2023
Same author

The ELFIN Mission.

Space science reviews·2020
Same author

Recommendations on surveillance and management of biallelic mismatch repair deficiency (BMMRD) syndrome: a consensus statement by the US Multi-Society Task Force on Colorectal Cancer.

Gastrointestinal endoscopy·2017
Same author

Recommendations on Surveillance and Management of Biallelic Mismatch Repair Deficiency (BMMRD) Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer.

Gastroenterology·2017
Same author

Recommendations on Surveillance and Management of Biallelic Mismatch Repair Deficiency (BMMRD) Syndrome: A Consensus Statement by the US Multi-society Task Force on Colorectal Cancer.

Journal of pediatric gastroenterology and nutrition·2017
Same author

Recommendations on Surveillance and Management of Biallelic Mismatch Repair Deficiency (BMMRD) Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer.

The American journal of gastroenterology·2017

Area of Science:

  • Oncology
  • Molecular Diagnostics
  • Gastroenterology

Background:

  • Colorectal cancer is a leading cause of cancer death, with current screening methods having limitations.
  • Existing tools like colonoscopy are invasive and costly, while noninvasive options face adherence and sensitivity issues.
  • There is a need for effective, noninvasive screening strategies with high patient acceptance and reliable access.

Purpose of the Study:

  • To review the limitations of current colorectal cancer screening tools.
  • To explore the potential of advanced molecular techniques, specifically stool-based DNA testing, as a noninvasive screening strategy.
  • To discuss the future prospects and ongoing research in refining stool-based DNA testing for colorectal cancer detection.

Main Methods:

Related Experiment Videos

  • Review of existing literature on colorectal cancer screening modalities.
  • Analysis of the performance, patient acceptability, and implementation barriers of various screening tools.
  • Discussion of molecular techniques for identifying DNA markers in exfoliated colonocytes.

    • Main Results:

    • Current screening tools, including colonoscopy and fecal occult blood testing (FOBT), have significant limitations in performance, cost, and patient adherence.
    • Noninvasive strategies, particularly stool-based DNA testing, show promise for population-based screening due to ease of use and potential for higher patient satisfaction.
    • Ongoing large-scale trials are expected to provide crucial data on the accuracy, cost-effectiveness, and adherence of stool-based DNA testing compared to FOBT.

    Conclusions:

    • Advanced stool-based DNA testing represents a significant advancement in noninvasive colorectal cancer screening.
    • Further research and large-scale trials are essential to fully characterize the performance and clinical utility of these molecular tests.
    • Refinements in multi-assay stool-based DNA testing hold promise for enhanced detection of this genetically diverse disease.